This phase II trial compares standard of care surgical resection to fluorescence-guided surgical resection using indocyanine green and fluorescence imaging for reducing unexpected positive margin rates in patients with sarcoma. Surgical margins are one of the criteria used in assessing the effectiveness of a given surgical procedure. They are the edges or border of the tissue removed in cancer surgery. A negative margin means that the resected tumor is surrounded by normal tissue, which implies there is no disease left in the patient. By contrast, a positive margin means that sarcoma cells are visible at the edge of the tumor. Positive margins may be classified as planned when they are expected pre-operatively due to the preservation of a critical structure, or unexpected when the pathologist reports the presence of tumor at the margin despite the surgeon having intended to remove it in its entirety. Fluorescence-guided surgery is an established surgical method that involves the administration of fluorescent dye (in this case, indocyanine green) into the tumor, which can then be visualized with a special camera during surgery to help surgeons identify tumor versus healthy tissue. Fluorescence-guided surgery may reduce the rate of unexpected positive margins in patients undergoing surgery for sarcoma.

Start Date15 May 2027

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT07481760

/ Not yet recruitingNot ApplicableIIT

Multicenter Randomized Controlled Trial Evaluating Indocyanine Green Fluorescence to Reduce Biliary Complications in Emergency Cholecystectomy for Acute Cholecystitis

Acute cholecystitis is a common indication for emergency laparoscopic cholecystectomy. Inflammatory changes and distorted anatomy may increase the risk of biliary complications, including bile duct injury and bile leak, which are associated with significant morbidity, reinterventions, and prolonged hospitalization. Indocyanine green (ICG) fluorescence cholangiography allows real-time visualization of the extrahepatic biliary anatomy using near-infrared imaging and has shown to improve anatomical identification during elective cholecystectomy. However, its clinical impact in the emergency setting of acute cholecystitis has not been adequately evaluated in randomized multicenter trials.
The objective of this study is to determine whether the use of ICG fluorescence cholangiography during emergency laparoscopic cholecystectomy reduces the incidence of clinically relevant biliary complications compared with standard surgery without ICG.
This is a pragmatic, multicenter, open-label randomized controlled trial including 296 adult patients with acute cholecystitis undergoing urgent laparoscopic cholecystectomy. Participants will be randomized 1:1 to surgery with or without ICG fluorescence guidance. The primary outcome is the incidence of clinically relevant biliary complications, including bile duct injury or bile leak, within 90 days after surgery.

Start Date01 Jan 2027

Sponsor / Collaborator

Hospital del Mar

NCT05038098

/ Not yet recruitingPhase 1IIT

Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial

This phase I finds out the possible benefits and/or side effects of using magnetic tracer FerroTrace and the fluorescent dye indocyanine green to identify the lymph nodes that cancer is most likely to have spread to in patients with gastric cancer that are undergoing gastrectomy. Using FerroTrace in combination with the indocyanine green dye may help researchers better detect the disease.

Start Date31 Dec 2026

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

100 Clinical Results associated with Indocyanine Green

100 Translational Medicine associated with Indocyanine Green

100 Patents (Medical) associated with Indocyanine Green

5,922

Literatures (Medical) associated with Indocyanine Green

01 Feb 2027·BIOMATERIALS

Coassembled peptide nanoparticles enable stage-specific diagnosis and targeted therapy of hepatic fibrosis by inhibiting macrophage-driven inflammation

Article

Author: Li, Bowen ; Ma, Yuerong ; Bao, Jianwei ; Zou, Qianli ; Pan, Chenchen

Hepatic fibrosis represents a major unmet clinical challenge, given its insidious progression and the lack of effective diagnostic and therapeutic strategies. To address this gap, we constructed supramolecular assemblies integrating an antifibrotic peptide with indocyanine green (ICG), a clinically approved dye for hepatic function assessment. The resulting ICG-peptide nanoparticles (ICG-peptide-NPs) integrate the therapeutic activity of the antifibrotic peptide with the diagnostic capacity of ICG. They significantly extend the diagnostic window of ICG from 15 to 60 min and improve diagnostic performance for liver fibrosis staging. Benefiting from prolonged blood circulation and selective accumulation in fibrotic liver tissue, ICG-peptide-NPs exhibit markedly enhanced antifibrotic efficacy. Mechanistically, they inhibit macrophage M1 polarization through the FPR2/STAT3 pathway. This effect reduces inflammatory factor secretion, suppresses extracellular matrix deposition, and normalizes serum liver function markers. We further demonstrate that ICG-peptide-NPs dampen aberrant immune responses during liver fibrosis progression by blocking the recruitment of monocyte-derived macrophages. The FPR2/STAT3-mediated signaling pathway is further validated at the transcriptomic level via whole-genome RNA sequencing. With favorable biocompatibility and enhanced antifibrotic efficacy, these multifunctional peptide assemblies offer a novel strategy for the integrated diagnosis and treatment of hepatic fibrosis.

01 Dec 2026·JOURNAL OF BIOLOGICAL PHYSICS

Coupled optical-thermal-chemical modeling of pulsed 808-nm ICG phototherapy using Monte Carlo photon transport

Article

Author: J M Tamimi, Zeina ; Gide, Bashir ; Al Timimi, Zahra

Phototherapy using indocyanine green (ICG) has been shown to utilize photothermal and photodynamic effects, and its effectiveness is determined through complex interactions of light transport, heat generation, and reactive oxygen species (ROS) production. In this paper, we report a computational framework for simulating the pulsed 808-nm photoactivation of ICG in a three-dimensional tumor spheroid. Photon transport in the heterogeneous spheroid domain is simulated using GPU-accelerated Monte Carlo photon transport, and the absorbed optical energy is coupled with a transient bioheat equation, an oxygen diffusion-reaction equation, and ROS production equation. The computational domain was defined as a voxelized spheroid with dimensions of 100 × 100 × 100 voxels, which represented the hypoxic tumor core and proliferative tumor areas. The simulation revealed that the fluence distribution is heterogeneous with significant attenuation, with about 70% being reduced within the first 400 µm. The maximum temperature ranged from 41.2 ± 0.6 to 53.6 ± 1.4 °C based on the pulse duration. The oxygen-dependent ROS generation was found to be highest in the oxygenated proliferative shell, whereas the hypoxic tumor core presented reduced photodynamic effects. The coupled cytotoxicity simulation revealed apoptotic-dominant areas in the oxygen-enriched tumor and necrosis due to heat in the case of increased pulse energy. The pulse duration, oxygen diffusion coefficient, and ICG absorption strength were found to be the most significant parameters affecting the treatment outcome based on the sensitivity analysis. The proposed multiphysics approach can be used as a quantitative tool to analyze laser-induced tumor phototherapy and can be helpful in the computational optimization of the treatment approach. The model is physics-based, and it predicts relative response tendencies to therapy rather than actual biological responses.

01 Dec 2026·COLLOIDS AND SURFACES B-BIOINTERFACES

NIR-activated antimicrobial peptide-functionalized nanoparticles for eradication of biofilms and healing of infected diabetic wounds

Article

Author: Shi, Linxuan ; Ma, Yiping ; Liu, Lu ; Bai, Yueping ; Wang, Shuo ; Li, Cui

The formation of bacterial biofilms at infection sites represents a major obstacle to the effective healing of diabetic wounds. Biofilm-associated diabetic wounds are exceedingly difficult to manage, compounded by the increasing prevalence of antibiotic-resistant strains and the limited pipeline of novel antibacterial agents. To address this challenge, we designed polydopamine-HHC36-indocyanine green nanoparticles (PHI NPs) as an alternative therapeutic platform to conventional antibiotics. PHI NPs were fabricated by encapsulating the phototherapeutic agent indocyanine green (ICG) within a polydopamine (PDA) matrix, followed by surface functionalization with the cationic antimicrobial peptide HHC36 for autonomous and selective pathogen targeting. In vitro, PHI NPs bound Staphylococcus aureus with high affinity. Following intravenous administration in vivo, PHI NPs effectively accumulated at infected sites in a murine diabetic wound model. Upon near-infrared (NIR) laser irradiation, PHI NPs disrupted the biofilm architecture and subsequently eradicated the exposed bacteria through synergy between phototherapy (combining photothermal and photodynamic effects) and the antimicrobial peptide. Notably, bactericidal efficacy was robust under mild photothermal conditions (<45 °C), ensuring a favorable safety profile. In conclusion, PHI NPs constitute a potent and biocompatible platform for eradicating biofilm-associated infections and promoting wound healing of diabetic wounds whilst avoiding induction of antibiotic resistance.

News (Medical) associated with Indocyanine Green

23 Sep 2026

·www.prnewswire.com

Sagent Pharmaceuticals Launches Zyogreen®, the First and Only Ready-to-Use Indocyanine Green Injection in the U.S.

New ready-to-use fluorescent imaging agent eliminates reconstitution at the point of care, giving surgical and imaging teams a differentiated option for fluorescence-guided procedures Sept. 22, 2026 -- Sagent Pharmaceuticals ("Sagent"), a leading provider of generic and specialty pharmaceuticals, today announced that Zyogreen® (indocyanine green injection), the first and only FDA-approved ready-to-use (RTU) indocyanine green (ICG) injection in the United States, is now commercially available. The U.S. market for indocyanine green was approximately $128 million for the twelve months ended July 2026 (IQVIA). Zyogreen is marketed and distributed in the U.S. by Sagent under an agreement with Provepharm, a global leader in medical and diagnostic dyes. Zyogreen is an optical imaging agent used in fluorescence-guided procedures and diagnostic imaging. Surgeons performing vascular, gastrointestinal, organ transplant, plastic, and reconstructive procedures – including minimally invasive surgery – as well as those visualizing extrahepatic biliary ducts, gynecologic oncologists performing lymphatic mapping in cervical and uterine cancer, and ophthalmologists performing angiography now have access to a ready-to-use ICG formulation. Unlike conventional ICG products, which are supplied as a lyophilized powder that must be reconstituted before administration, Zyogreen is supplied as a sterile solution with no reconstitution required. For visualization of extrahepatic biliary ducts, Zyogreen is indicated in adults and in pediatric patients from birth to less than 1 year of age and 6 years of age and older. "This launch represents another important milestone in Sagent's evolution as a specialty pharmaceutical company," said Vishy Chebrol, Chief Executive Officer of Sagent Pharmaceuticals. "Zyogreen brings the established clinical utility of indocyanine green together with the convenience of a ready-to-use formulation, and it adds another FDA-approved source of a product that surgical and imaging teams depend on. Through our partnership with Provepharm, we are working to strengthen the reliability of supply for the hospitals and health systems we serve and to support the growing use of fluorescence-guided imaging." "Zyogreen is a true innovation emerging from Provepharm's research and development expertise, introducing a ready-to-use formulation to fluorescence imaging," said Michel Feraud, chairman and founder of Provepharm. "Partnering with Sagent brings that innovation to hospitals and surgical teams across the United States, and reflects our long-term commitment to supporting healthcare professionals and the patients in their care." Zyogreen is the second Provepharm dye Sagent has brought to the U.S. market, joining Bludigo® (indigotindisulfonate sodium injection), the first and only FDA-approved injectable indigo carmine diagnostic dye. Together, the two products establish Sagent's growing presence in surgical and diagnostic visualization and provide a strong foundation for continued growth in this evolving field. Zyogreen is available now through Sagent's nationwide distribution network. Zyogreen® (indocyanine green injection) is a sterile, ready-to-use optical imaging agent for intravenous or interstitial use. Zyogreen is indicated for fluorescence imaging of vessels, blood flow and tissue perfusion in adults and pediatric patients; fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients from birth to less than 1 year of age and 6 years of age and older; fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer; and ophthalmic angiography in adults and pediatric patients. Please see full Prescribing Information for complete indication and safety information. Sagent Pharmaceuticals is a leading provider of generic and specialty pharmaceuticals serving hospitals, health systems, and healthcare providers throughout the United States. Through strategic partnerships, advanced drug delivery technologies, and a growing portfolio of differentiated products, Sagent is committed to delivering high-quality medicines that support patient care and improve healthcare delivery. Sagent is headquartered in Schaumburg, Illinois. Provepharm is a pharmaceutical company specializing in the development of high-quality, effective and ready-to-use dyes designed to improve visualization and detection in clinical practice. With almost 30 years of expertise, our innovation is grounded in organic chemistry and advanced formulation technologies, ensuring the quality, performance and ease of use of our dyes in the operating room. www.provepharm.com Zyogreen® and Bludigo® are registered trademarks of Provepharm SAS. The content above comes from the network. if any infringement, please contact us to modify.

Drug Approval

23 Sep 2026

·www.biospace.com

Sagent Pharmaceuticals Launches Zyogreen®, the First and Only Ready-to-Use Indocyanine Green Injection in the U.S.

New ready-to-use fluorescent imaging agent eliminates reconstitution at the point of care, giving surgical and imaging teams a differentiated option for fluorescence-guided procedures SCHAUMBURG, Ill. , Sept. 22, 2026 /PRNewswire/ -- Sagent Pharmaceuticals ("Sagent"), a leading provider of generic and specialty pharmaceuticals, today announced that Zyogreen® (indocyanine green injection) , the first and only FDA-approved ready-to-use (RTU) indocyanine green (ICG) injection in the United States, is now commercially available. The U.S. market for indocyanine green was approximately $128 million for the twelve months ended July 2026 (IQVIA). Zyogreen is marketed and distributed in the U.S. by Sagent under an agreement with Provepharm, a global leader in medical and diagnostic dyes. Zyogreen is an optical imaging agent used in fluorescence-guided procedures and diagnostic imaging. Surgeons performing vascular, gastrointestinal, organ transplant, plastic, and reconstructive procedures – including minimally invasive surgery – as well as those visualizing extrahepatic biliary ducts, gynecologic oncologists performing lymphatic mapping in cervical and uterine cancer, and ophthalmologists performing angiography now have access to a ready-to-use ICG formulation. Unlike conventional ICG products, which are supplied as a lyophilized powder that must be reconstituted before administration, Zyogreen is supplied as a sterile solution with no reconstitution required. For visualization of extrahepatic biliary ducts, Zyogreen is indicated in adults and in pediatric patients from birth to less than 1 year of age and 6 years of age and older. "This launch represents another important milestone in Sagent's evolution as a specialty pharmaceutical company," said Vishy Chebrol, Chief Executive Officer of Sagent Pharmaceuticals. "Zyogreen brings the established clinical utility of indocyanine green together with the convenience of a ready-to-use formulation, and it adds another FDA-approved source of a product that surgical and imaging teams depend on. Through our partnership with Provepharm, we are working to strengthen the reliability of supply for the hospitals and health systems we serve and to support the growing use of fluorescence-guided imaging." "Zyogreen is a true innovation emerging from Provepharm's research and development expertise, introducing a ready-to-use formulation to fluorescence imaging," said Michel Feraud, chairman and founder of Provepharm. "Partnering with Sagent brings that innovation to hospitals and surgical teams across the United States, and reflects our long-term commitment to supporting healthcare professionals and the patients in their care." Zyogreen is the second Provepharm dye Sagent has brought to the U.S. market, joining Bludigo® (indigotindisulfonate sodium injection) , the first and only FDA-approved injectable indigo carmine diagnostic dye. Together, the two products establish Sagent's growing presence in surgical and diagnostic visualization and provide a strong foundation for continued growth in this evolving field. Zyogreen is available now through Sagent's nationwide distribution network. Important Safety Information Contraindications: Zyogreen is contraindicated in patients with a history of hypersensitivity to indocyanine green. Reactions have included anaphylaxis. Warnings and Precautions: Hypersensitivity reactions, including anaphylaxis, urticaria, and deaths due to anaphylaxis, have been reported following intravenous administration of indocyanine green, the active ingredient in Zyogreen. Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions. Because Zyogreen contains sodium iodine, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration. Drug Interactions: Do not perform radioactive iodine uptake studies for at least one week following administration of Zyogreen. Adverse Reactions: The most common adverse reactions reported are anaphylaxis and urticaria. To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-800-625-1618 or FDA at 1-800-FDA-1088 or . Please see full Prescribing Information for complete indication and safety information. About Zyogreen® Zyogreen® (indocyanine green injection) is a sterile, ready-to-use optical imaging agent for intravenous or interstitial use. Zyogreen is indicated for fluorescence imaging of vessels, blood flow and tissue perfusion in adults and pediatric patients; fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients from birth to less than 1 year of age and 6 years of age and older; fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer; and ophthalmic angiography in adults and pediatric patients. Please see full Prescribing Information for complete indication and safety information. About Sagent Pharmaceuticals Sagent Pharmaceuticals is a leading provider of generic and specialty pharmaceuticals serving hospitals, health systems, and healthcare providers throughout the United States. Through strategic partnerships, advanced drug delivery technologies, and a growing portfolio of differentiated products, Sagent is committed to delivering high-quality medicines that support patient care and improve healthcare delivery. Sagent is headquartered in Schaumburg, Illinois. For more information, visit . About Provepharm Provepharm is a pharmaceutical company specializing in the development of high-quality, effective and ready-to-use dyes designed to improve visualization and detection in clinical practice. With almost 30 years of expertise, our innovation is grounded in organic chemistry and advanced formulation technologies, ensuring the quality, performance and ease of use of our dyes in the operating room. Zyogreen® and Bludigo® are registered trademarks of Provepharm SAS. MEDIA CONTACT: Sagent Pharmaceuticals Jeff Greve EVP, Chief Financial Officer (312) 331-0050 jgreve@sagentpharma.com Jyothi Chaludavi Vice President, Business Development and Strategic Initiatives +91 73309-99114 jchaludavi@sagentpharma.com View original content to download multimedia: SOURCE Sagent Pharmaceuticals

Drug Approval

05 Aug 2026

·www.pharmaindustrial-india.com

Zydus Wins US FDA Approval for Generic Indocyanine Green Injection

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Indocyanine Green for Injection, USP, 25 mg/vial, a sterile lyophilised powder for reconstitution. The company stated that Indocyanine Green for Injection is the generic equivalent of the Reference Listed Drug (RLD), IC-Green by Diagnostic Green. The FDA has designated the application as a Competitive Generic Therapy (CGT). According to the company, eligibility for the 180-day exclusivity available to certain CGTs is determined by the FDA and, where applicable, the period begins from the date of first commercial marketing. Indocyanine Green for Injection is an optical imaging agent indicated for fluorescence imaging of vessels, blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro and reconstructive surgeries, including general minimally invasive surgical procedures. It is also indicated for fluorescence imaging of extrahepatic biliary ducts, fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer, and ophthalmic angiography. The product is indicated for use in adults and, for certain indications, in pediatric patients aged 1 month and older. The product will be manufactured at the group’s FDA-approved injectable manufacturing facility at Jarod, near Vadodara, Gujarat, and will be marketed in the US by Zydus Pharmaceuticals USA. Commenting on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, said, “Indocyanine green sits at the intersection of medicine and imaging science, requiring precise control of chromophore purity, photostability and lyophilisation. Developing and securing approval for such a complex product with our partner reflects the capabilities we have built and our shared commitment to high standards. It also advances our goal of making essential medicines and diagnostics more accessible, while strengthening our presence in the functional dye and imaging agent segment, where we continue to invest.” The approval adds to its portfolio of injectable and imaging products and reflects a development model combining internal formulation and analytical capabilities with an external partner selected for the programme. Zydus added that it continues to invest in the functional dye and imaging agent segment. The product will be supplied as a kit containing single-patient-use vials of Indocyanine Green for Injection, 25 mg, as a sterile lyophilised green powder for reconstitution, together with single-dose vials of Sterile Water for Injection, 10 ml.

Drug Approval

100 Deals associated with Indocyanine Green

External Link

KEGG	Wiki	ATC	Drug Bank
D01342	Indocyanine Green	V04CX01	DB09374

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bile Duct Diseases	United States	Novadaq Technologies ULC	21 Nov 2018
Uterine Cervical Cancer	United States	Novadaq Technologies ULC	21 Nov 2018
Uterine Neoplasms	United States	Novadaq Technologies ULC	21 Nov 2018
Vascular Diseases	United States	Novadaq Technologies ULC	21 Nov 2018
Breast Cancer	Japan	Daiichi Sankyo Co., Ltd.	18 Sep 2009
Melanoma	Japan	Daiichi Sankyo Co., Ltd.	18 Sep 2009
Contrast agents	United States	Renew Pharmaceuticals Ltd.	09 Feb 1959

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Liver Failure, Acute	Phase 3	United States	CardioX, Inc.	01 Nov 2015
Colonic Cancer	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Esophageal Carcinoma	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Glioma	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Meningioma	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Non-Small Cell Lung Cancer	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Ovarian Cancer	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Pancreatic Cancer	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Parathyroid Adenoma	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Prostatic Cancer	Phase 2	United States	University of Pennsylvania	14 Aug 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03584633 (CTgov)	Phase 4	Lymphedema	9	Indocyanine green	eicxiauxzt(dnttdsnjdd) = gazimsxock qjbuovheey (xpamwcckmb, 1) View more	-	27 Dec 2024
NCT04534816 (Pubmed \| Int J Surg)	Not Applicable	Wounds, Penetrating	-	Indocyanine green (ICG-FA)	bgaoljiwdp(wijpyuntmp) = yhpmqjftoy diuclgbgng (kjblmludaj ) View more	Positive	01 Dec 2024
NCT04534816 (Pubmed \| Int J Surg)	Not Applicable	Wounds, Penetrating	-	Indocyanine green (Control (no ICG-FA))	iyaolaijiq(oubpmfttjs) = zopbbbhhkw ozujalapoe (jajwqikzyr ) View more	Positive	01 Dec 2024
NCT05859971 (CTgov)	Early Phase 1	Breast Cancer	10	isosulfan blue+SLN mapping with ICG fluorescence using the Asimov Platform	looliiklzg = snpzbxvjeo qmbprxartk (oiizckonzv, gepqgabkaf - tedndtkryf) View more	-	15 Aug 2024
NCT01034670 (CTgov)	Not Applicable	Gastrointestinal Stromal Tumors \| Stomach Cancer	3	fluorescent Peptide+fluorescein+Indocyanine green	iijombayor = ytjqskbged tjhcklvsmy (yggtaqscrz, szwdqvxgyu - yfqynsinkd) View more	-	26 Jun 2024
NCT05094102 (CTgov)	Not Applicable	Breast Cancer \| Lymphedema	9	OnLume Imaging System+Indocyanine green	dhgmjblvlo = glusdtkoku njbiedkdoi (lmyadcwzwr, wxrsistjiy - oliybifbbk) View more	-	23 May 2024
NCT04511026 (CTgov)	Phase 2	Endometrial Carcinoma	6	Single Photon Emission Computed Tomography (SPECT)+Lymphoseek+Indocyanine Green (ICG)	kssgjbwlxa = acwzfcxxlm jdfjjgyigc (spvcooaqyc, kfbmwdukxz - nzxwjmkryf) View more	-	11 Oct 2023
NCT04084067 (Pubmed \| Pediatr Blood Cancer)	Phase 1	Solid tumor	12	Indocyanine green (ICG)	ruhodwujve(ewtibfyjrx) = ICG guidance failed to localize pulmonary metastases in five (42%) patients who had inflammatory myofibroblastic tumor, atypical cartilaginous tumor, neuroblastoma, adrenocortical carcinoma, or papillary thyroid carcinoma rfbyvfwzbz (sgyeczciss )	Negative	01 Oct 2023
NCT03200704 (FILM-B, CTgov)	Phase 3	Breast Cancer	152	Tc-99m radioactive colloid and Gamma Probe+IC2000 and SPY-PHI	pbxpkrpnhx = chiloesggr whljlpojmw (esckzgjdkq, xovoguambj - ioqwtnibsz) View more	-	21 Sep 2023
NCT04942665 (ICG, CTgov)	Phase 2	Hepatocellular Carcinoma \| Liver metastases \| Cholecystitis	60	PINPOINT Endoscopic Fluorescence+Indocyanine green (Low Dose)	ckezyzuakj(iagoauuvbg) = hnsrtvpuiu dsaryzncnp (ibueehurim, kosmmntirk - ukilxrjpea) View more	-	30 Aug 2023
NCT04942665 (ICG, CTgov)	Phase 2	Hepatocellular Carcinoma \| Liver metastases \| Cholecystitis	60	PINPOINT Endoscopic Fluorescence+Indocyanine green (Standard Dose)	ckezyzuakj(iagoauuvbg) = yxjjeceops dsaryzncnp (ibueehurim, xkndykifdc - yiuclvvlsv) View more	-	30 Aug 2023
NCT03294330 (SPYX, CTgov)	Phase 3	Melanoma, Cutaneous Malignant \| Breast Cancer	35	IC-Green KIT	eaimbpiyqf = smtbwrtkaa hakchjqinh (gfcsjrrknl, zvnmrpldro - rmrqmfyuux) View more	-	12 Jan 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis